OVERSEA CHINESE BANKING Corp Ltd Decreases Position in Agilent Technologies, Inc. (NYSE:A)

OVERSEA CHINESE BANKING Corp Ltd trimmed its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 12.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 260,393 shares of the medical research company’s stock after selling 37,992 shares during the period. Agilent Technologies comprises approximately 1.1% of OVERSEA CHINESE BANKING Corp Ltd’s portfolio, making the stock its 21st largest position. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Agilent Technologies were worth $38,663,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of A. Livelsberger Financial Advisory bought a new position in shares of Agilent Technologies in the third quarter worth approximately $28,000. Crewe Advisors LLC grew its holdings in Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after acquiring an additional 101 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Agilent Technologies in the third quarter valued at about $31,000. Ridgewood Investments LLC bought a new position in shares of Agilent Technologies during the second quarter valued at about $29,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after purchasing an additional 95 shares during the period.

Insider Transactions at Agilent Technologies

In related news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares of the company’s stock, valued at $5,801,595. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares of the company’s stock, valued at $3,497,110. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,995 shares of company stock valued at $1,739,510 in the last quarter.

Agilent Technologies Trading Down 2.1 %

NYSE:A opened at $133.86 on Tuesday. Agilent Technologies, Inc. has a one year low of $106.96 and a one year high of $155.35. The company’s 50-day simple moving average is $139.46 and its 200 day simple moving average is $138.21. The firm has a market capitalization of $38.46 billion, a P/E ratio of 27.77, a PEG ratio of 6.01 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the previous year, the firm posted $1.43 EPS. The business’s revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, analysts forecast that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were issued a dividend of $0.236 per share. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 annualized dividend and a dividend yield of 0.71%. Agilent Technologies’s payout ratio is presently 19.50%.

Wall Street Analysts Forecast Growth

A has been the topic of a number of research analyst reports. Wells Fargo & Company initiated coverage on Agilent Technologies in a report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price target on the stock. Stifel Nicolaus reissued a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research note on Monday, August 26th. Barclays raised their price target on Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a research note on Tuesday, October 15th. TD Cowen boosted their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, Bank of America upped their price objective on shares of Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $144.36.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.